| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.4 nM (porcine PREP)[2] Ki: 3.7 nM (PREP from bovine brain)[1]
Prolyl endopeptidase (PREP/POP) with IC50 = 0.4 nM (porcine) and Ki = 1 nM. Z-Pro-prolinal is a highly specific inhibitor that binds in the S1 proline-binding pocket of the enzyme. |
|---|---|
| ln Vitro |
Z-Pro-prolinal potently inhibits PREP enzymatic activity with an IC50 of 0.4 nM for the porcine enzyme. At nanomolar concentrations, it effectively blocks cleavage of peptide substrates containing proline residues, preventing the release of neuroactive peptides such as substance P, neurotensin, and TRH.
|
| ln Vivo |
Rats' septal vasopressin content is increased by Z-Pro-prolinal (N-Benzyloxycarbonyl-L-prolyl-L-prolinal) (100 mg/kg; po; once)[3].
Z-Pro-prolinal is orally active. It has been used to study PREP function in animal models of neurodegeneration and cognitive impairment. Oral administration can regulate brain levels of peptide substrates involved in memory, mood, and neuroprotection, though specific in vivo efficacy data vary by study. |
| Enzyme Assay |
For non-cellular enzyme assays, PREP enzyme (porcine or recombinant) is incubated with a fluorogenic substrate such as Z-Gly-Pro-AMC (excitation 380 nm, emission 460 nm) in assay buffer at pH 7.4. Z-Pro-prolinal is added at varying concentrations (0.01-100 nM), and the reaction is monitored continuously for 30-60 minutes to calculate IC50 values.
|
| Cell Assay |
For cell-based assays, CV1-P (monkey fibroblast) or other cell lines are pretreated with Z-Pro-prolinal (30 microM, 30 min) prior to exposure to 6-hydroxydopamine (6-OHDA) or other toxicants. GAPDH translocation is analyzed by Western blot, ROS production by fluorescent DCFH-DA, and viability by MTT assay.
|
| Animal Protocol |
Animal/Disease Models: Male Wistar rats[3]
Doses: 100 mg/kg Route of Administration: Oral administration, once Experimental Results: Dramatically increased the septal arginine-vasopressin (AVP) content. For in vivo studies, Z-Pro-prolinal is administered orally (typically 1-10 mg/kg) or intraperitoneally to rodents. Tissues such as brain, plasma, or specific organs are collected, and PREP activity is measured ex vivo using fluorogenic substrate assays. Behavioral tests may assess cognitive function or memory. |
| ADME/Pharmacokinetics |
Z-Pro-prolinal is orally bioavailable. It can be formulated in vehicles such as DMSO/PEG300/Tween-80/saline for administration. Its half-life and metabolic stability have been characterized in rodent models, with detectable levels in plasma and brain following oral administration.
|
| Toxicity/Toxicokinetics |
Z-Pro-prolinal has been evaluated in preclinical safety studies as a research tool. At typical research doses (1-30 mg/kg), it is generally well tolerated. Detailed toxicological profiles in the context of drug development are limited, as it is primarily used as a chemical probe.
|
| References |
|
| Additional Infomation |
See also: N-benzyloxycarbonylprolylproline aldehyde (note moved to).
Z-Pro-prolinal (CAS: 88795-32-8) has molecular formula C18H22N2O4 and molecular weight 330.38. It is a potent PREP inhibitor that has been connected to the regulation of memory-related peptides. It is not approved for clinical use and is intended for research applications investigating PREP biology and neurodegeneration. |
| Molecular Formula |
C18H22N2O4
|
|---|---|
| Molecular Weight |
330.38
|
| Exact Mass |
330.158
|
| CAS # |
88795-32-8
|
| PubChem CID |
122623
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.853
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
476
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C([C@@H]1CCCN1C(=O)OCC1C=CC=CC=1)N1CCC[C@H]1C=O
|
| InChi Key |
ORZXYSPOAVJYRU-HOTGVXAUSA-N
|
| InChi Code |
InChI=1S/C18H22N2O4/c21-12-15-8-4-10-19(15)17(22)16-9-5-11-20(16)18(23)24-13-14-6-2-1-3-7-14/h1-3,6-7,12,15-16H,4-5,8-11,13H2/t15-,16-/m0/s1
|
| Chemical Name |
benzyl (2S)-2-[(2S)-2-formylpyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0268 mL | 15.1341 mL | 30.2682 mL | |
| 5 mM | 0.6054 mL | 3.0268 mL | 6.0536 mL | |
| 10 mM | 0.3027 mL | 1.5134 mL | 3.0268 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
